Monocytosis in polycythemia vera: Clinical and molecular correlates

Daniela Barraco, Sonia Cerquozzi, Naseema Gangat, Mrinal M Patnaik, Terra Lasho, Christy Finke, Curtis A. Hanson, Rhett P. Ketterling, Animesh D Pardanani, Ayalew Tefferi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Monocytosis (absolute monocyte count, AMC ≥ 1 × 109/L) might accompany a spectrum of myeloid neoplasms, other than chronic myelomonocytic leukemia (CMML). In the current study, we examined the prevalence, laboratory and molecular correlates, and prognostic relevance of monocytosis in polycythemia vera (PV). Among 267 consecutive patients with World Health Organization (WHO)-defined PV, 55 (21%) patients displayed an AMC of ≥1 × 109/L and 18 (7%) an AMC of ≥1.5 × 109/L. In general, PV patients with monocytosis were significantly older and displayed higher frequencies of leukocytosis (81% vs. 50% at AMC ≥1 × 109/L) and TET2/SRSF2 mutations (57%/29% vs. 19%/1% at AMC ≥ 1.5 × 109/L). In univariate analysis, AMC ≥1.5 × 109/L adversely affected overall (OS; P =.004; HR 2.6, 95% CI 1.4-4.8) and myelofibrosis-free (MFFS; P =.02; HR 4.4, 95% CI 1.3-15.1) survival; during multivariable analysis, significance was borderline sustained for OS (P =.05) and MFFS (P =.06). Other independent risk factors for OS included unfavorable karyotype (P =.02, HR 3.39, 95% CI 1.17-9.79), older age (P <.0001, HR 3.34 95% CI 1.97-5.65), and leukocytosis ≥15 × 109/L (P =.004, HR 2.04, 95% CI 1.26-3.29). In conclusion, in the current study, we encountered a higher than expected prevalence of monocytosis in patients with PV and the mutation profile and age distribution of PV patients with monocytosis is akin to those of patients with CMML and might partly contribute to their worse prognosis.

Original languageEnglish (US)
Pages (from-to)640-645
Number of pages6
JournalAmerican Journal of Hematology
Volume92
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Polycythemia Vera
Leukemia, Myelomonocytic, Chronic
Leukocytosis
Primary Myelofibrosis
Mutation
Age Distribution
Karyotype
Monocytes
Survival
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Monocytosis in polycythemia vera : Clinical and molecular correlates. / Barraco, Daniela; Cerquozzi, Sonia; Gangat, Naseema; Patnaik, Mrinal M; Lasho, Terra; Finke, Christy; Hanson, Curtis A.; Ketterling, Rhett P.; Pardanani, Animesh D; Tefferi, Ayalew.

In: American Journal of Hematology, Vol. 92, No. 7, 01.07.2017, p. 640-645.

Research output: Contribution to journalArticle

Barraco, D, Cerquozzi, S, Gangat, N, Patnaik, MM, Lasho, T, Finke, C, Hanson, CA, Ketterling, RP, Pardanani, AD & Tefferi, A 2017, 'Monocytosis in polycythemia vera: Clinical and molecular correlates', American Journal of Hematology, vol. 92, no. 7, pp. 640-645. https://doi.org/10.1002/ajh.24740
Barraco, Daniela ; Cerquozzi, Sonia ; Gangat, Naseema ; Patnaik, Mrinal M ; Lasho, Terra ; Finke, Christy ; Hanson, Curtis A. ; Ketterling, Rhett P. ; Pardanani, Animesh D ; Tefferi, Ayalew. / Monocytosis in polycythemia vera : Clinical and molecular correlates. In: American Journal of Hematology. 2017 ; Vol. 92, No. 7. pp. 640-645.
@article{b60d09ba17b3441fba52ae766ec49af7,
title = "Monocytosis in polycythemia vera: Clinical and molecular correlates",
abstract = "Monocytosis (absolute monocyte count, AMC ≥ 1 × 109/L) might accompany a spectrum of myeloid neoplasms, other than chronic myelomonocytic leukemia (CMML). In the current study, we examined the prevalence, laboratory and molecular correlates, and prognostic relevance of monocytosis in polycythemia vera (PV). Among 267 consecutive patients with World Health Organization (WHO)-defined PV, 55 (21{\%}) patients displayed an AMC of ≥1 × 109/L and 18 (7{\%}) an AMC of ≥1.5 × 109/L. In general, PV patients with monocytosis were significantly older and displayed higher frequencies of leukocytosis (81{\%} vs. 50{\%} at AMC ≥1 × 109/L) and TET2/SRSF2 mutations (57{\%}/29{\%} vs. 19{\%}/1{\%} at AMC ≥ 1.5 × 109/L). In univariate analysis, AMC ≥1.5 × 109/L adversely affected overall (OS; P =.004; HR 2.6, 95{\%} CI 1.4-4.8) and myelofibrosis-free (MFFS; P =.02; HR 4.4, 95{\%} CI 1.3-15.1) survival; during multivariable analysis, significance was borderline sustained for OS (P =.05) and MFFS (P =.06). Other independent risk factors for OS included unfavorable karyotype (P =.02, HR 3.39, 95{\%} CI 1.17-9.79), older age (P <.0001, HR 3.34 95{\%} CI 1.97-5.65), and leukocytosis ≥15 × 109/L (P =.004, HR 2.04, 95{\%} CI 1.26-3.29). In conclusion, in the current study, we encountered a higher than expected prevalence of monocytosis in patients with PV and the mutation profile and age distribution of PV patients with monocytosis is akin to those of patients with CMML and might partly contribute to their worse prognosis.",
author = "Daniela Barraco and Sonia Cerquozzi and Naseema Gangat and Patnaik, {Mrinal M} and Terra Lasho and Christy Finke and Hanson, {Curtis A.} and Ketterling, {Rhett P.} and Pardanani, {Animesh D} and Ayalew Tefferi",
year = "2017",
month = "7",
day = "1",
doi = "10.1002/ajh.24740",
language = "English (US)",
volume = "92",
pages = "640--645",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Monocytosis in polycythemia vera

T2 - Clinical and molecular correlates

AU - Barraco, Daniela

AU - Cerquozzi, Sonia

AU - Gangat, Naseema

AU - Patnaik, Mrinal M

AU - Lasho, Terra

AU - Finke, Christy

AU - Hanson, Curtis A.

AU - Ketterling, Rhett P.

AU - Pardanani, Animesh D

AU - Tefferi, Ayalew

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Monocytosis (absolute monocyte count, AMC ≥ 1 × 109/L) might accompany a spectrum of myeloid neoplasms, other than chronic myelomonocytic leukemia (CMML). In the current study, we examined the prevalence, laboratory and molecular correlates, and prognostic relevance of monocytosis in polycythemia vera (PV). Among 267 consecutive patients with World Health Organization (WHO)-defined PV, 55 (21%) patients displayed an AMC of ≥1 × 109/L and 18 (7%) an AMC of ≥1.5 × 109/L. In general, PV patients with monocytosis were significantly older and displayed higher frequencies of leukocytosis (81% vs. 50% at AMC ≥1 × 109/L) and TET2/SRSF2 mutations (57%/29% vs. 19%/1% at AMC ≥ 1.5 × 109/L). In univariate analysis, AMC ≥1.5 × 109/L adversely affected overall (OS; P =.004; HR 2.6, 95% CI 1.4-4.8) and myelofibrosis-free (MFFS; P =.02; HR 4.4, 95% CI 1.3-15.1) survival; during multivariable analysis, significance was borderline sustained for OS (P =.05) and MFFS (P =.06). Other independent risk factors for OS included unfavorable karyotype (P =.02, HR 3.39, 95% CI 1.17-9.79), older age (P <.0001, HR 3.34 95% CI 1.97-5.65), and leukocytosis ≥15 × 109/L (P =.004, HR 2.04, 95% CI 1.26-3.29). In conclusion, in the current study, we encountered a higher than expected prevalence of monocytosis in patients with PV and the mutation profile and age distribution of PV patients with monocytosis is akin to those of patients with CMML and might partly contribute to their worse prognosis.

AB - Monocytosis (absolute monocyte count, AMC ≥ 1 × 109/L) might accompany a spectrum of myeloid neoplasms, other than chronic myelomonocytic leukemia (CMML). In the current study, we examined the prevalence, laboratory and molecular correlates, and prognostic relevance of monocytosis in polycythemia vera (PV). Among 267 consecutive patients with World Health Organization (WHO)-defined PV, 55 (21%) patients displayed an AMC of ≥1 × 109/L and 18 (7%) an AMC of ≥1.5 × 109/L. In general, PV patients with monocytosis were significantly older and displayed higher frequencies of leukocytosis (81% vs. 50% at AMC ≥1 × 109/L) and TET2/SRSF2 mutations (57%/29% vs. 19%/1% at AMC ≥ 1.5 × 109/L). In univariate analysis, AMC ≥1.5 × 109/L adversely affected overall (OS; P =.004; HR 2.6, 95% CI 1.4-4.8) and myelofibrosis-free (MFFS; P =.02; HR 4.4, 95% CI 1.3-15.1) survival; during multivariable analysis, significance was borderline sustained for OS (P =.05) and MFFS (P =.06). Other independent risk factors for OS included unfavorable karyotype (P =.02, HR 3.39, 95% CI 1.17-9.79), older age (P <.0001, HR 3.34 95% CI 1.97-5.65), and leukocytosis ≥15 × 109/L (P =.004, HR 2.04, 95% CI 1.26-3.29). In conclusion, in the current study, we encountered a higher than expected prevalence of monocytosis in patients with PV and the mutation profile and age distribution of PV patients with monocytosis is akin to those of patients with CMML and might partly contribute to their worse prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85019679344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019679344&partnerID=8YFLogxK

U2 - 10.1002/ajh.24740

DO - 10.1002/ajh.24740

M3 - Article

C2 - 28370365

AN - SCOPUS:85019679344

VL - 92

SP - 640

EP - 645

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -